background
leukocytemedi
pulmonari
inflamm
key
pathophysiolog
mechan
involv
acut
respiratori
distress
syndrom
ard
massiv
sequestr
leukocyt
pulmonari
microvasculatur
major
trigger
event
syndrom
therefor
investig
potenti
role
leukocyt
stiff
adhes
sequestr
leukocyt
microvessel
method
studi
base
vitro
microfluid
assay
use
patient
sera
cell
stiff
assess
measur
entri
time
et
singl
cell
microchannel
crosssect
constant
pressur
drop
pa
primari
neutrophil
monocyt
well
monocyt
cell
line
use
cellular
adhes
human
umbil
vein
endotheli
cell
examin
use
laminar
flow
chamber
method
compar
properti
cell
incub
sera
healthi
volunt
n
patient
present
acut
cardiogen
pulmonari
edema
acp
n
patient
ard
n
classifi
moder
sever
diseas
remain
mild
diseas
result
rapid
strong
stiffen
primari
neutrophil
monocyt
induc
within
minut
mean
et
second
sera
ard
group
compar
healthi
subject
acp
group
mean
et
second
p
systemat
measur
cell
line
allow
establish
strong
correl
stiffen
sever
respiratori
statu
mean
et
second
healthi
subject
second
acp
group
second
mild
ard
second
moder
sever
ard
p
stiffen
correl
cytokin
interleukin
tumor
necrosi
factor
transform
growth
strong
stiffen
induc
incub
sera
block
antibodi
significantli
diminish
stiffen
effect
serum
contrast
measur
integrin
express
leukocyteendothelium
adhes
show
weak
slow
respons
incub
sera
patient
ard
sever
hour
suggest
lesser
role
leukocyt
adhes
compar
leukocyt
stiff
earli
ard
continu
next
page
continu
previou
page
conclus
leukocyt
stiffen
induc
cytokin
sera
patient
might
play
role
sequestr
leukocyt
lung
capillari
bed
earli
ard
inhibit
leukocyt
stiffen
block
antibodi
might
inspir
futur
therapeut
strategi
acut
respiratori
distress
syndrom
ard
identifi
bilater
pulmonari
inflammatori
condit
follow
direct
indirect
lung
injuri
rigor
clinic
manag
reduc
mortal
ard
mainli
owe
lack
understand
ard
pathophysiolog
sequestr
leukocyt
particularli
neutrophil
lung
microvasculatur
appear
key
determin
pathophysiolog
ard
lead
blood
circul
blockag
microthrombu
format
uncontrol
inflamm
injuri
alveolarcapillari
membran
research
attempt
clarifi
mechan
involv
leukocyt
sequestr
mani
studi
chang
leukocyt
adhes
vessel
wall
report
variou
inflamm
context
notabl
ard
vitro
studi
also
shown
fraction
circul
leukocyt
patient
ard
well
patient
sepsi
trauma
pneumonia
result
impair
deform
like
caus
densif
factin
cortic
region
suggest
role
leukocyt
stiffen
sequestr
leukocyt
lung
capillari
howev
role
leukocyt
adhes
stiff
remain
unclear
microcircul
impair
associ
abnorm
concentr
cytokin
endotoxin
variou
inflammatori
diseas
case
ard
rare
studi
moreov
consensu
conclus
difficult
draw
due
divers
experiment
condit
model
instanc
studi
fail
show
effect
interleukin
il
leukocyt
stiff
wherea
other
found
pronounc
effect
addit
tumor
necrosi
factor
tnf
report
promot
adher
condit
wherea
effect
detect
studi
altogeth
appear
trigger
event
ard
mainli
leukocyt
sequestr
lung
remain
larg
obscur
regard
mechan
biochem
signal
involv
present
studi
use
vitro
microfluid
method
investig
leukocyt
stiff
adhes
respons
incub
sera
patient
ard
time
requir
leukocyt
penetr
synthet
microchannel
allow
us
assess
stiff
leukocyt
wherea
laminar
flow
chamber
assay
use
character
adhes
main
object
studi
first
demonstr
sera
patient
ard
induc
leukocyt
stiffen
identifi
cytokin
condit
induc
leukocyt
stiffen
test
protect
treatment
prospect
observ
studi
conduct
medic
intens
care
unit
icu
teach
hospit
investig
approv
local
ethic
committe
assist
publiquehopitaux
de
marseil
consecut
mechan
ventil
patient
present
ard
defin
accord
berlin
definit
includ
earli
cours
diseas
within
day
ard
onset
lower
ratio
partial
pressur
oxygen
arteri
blood
fraction
inspir
oxygen
pao
fio
measur
use
classifi
patient
ard
accord
berlin
definit
patient
pao
fio
ratio
mmhg
assign
moder
sever
ard
group
patient
pao
fio
ratio
mmhg
assign
mild
ard
group
volum
assist
control
ventil
use
tidal
volum
mlkg
predict
bodi
weight
maxim
plateau
pressur
cmh
oxygen
goal
puls
oximetrymeasur
arteri
oxygen
satur
pao
mmhg
fio
posit
endexpiratori
pressur
adjust
arma
trial
five
healthi
volunt
medic
depart
serv
healthi
group
six
mechan
ventil
patient
acut
cardiogen
pulmonari
edema
acp
also
enrol
acp
group
septic
shock
ss
defin
accord
societi
critic
care
medicineeuropean
societi
intens
care
medicineamerican
colleg
chest
physiciansamerican
thorac
societysurg
infect
societi
intern
sepsi
definit
confer
criteria
patient
present
immunolog
treatment
neoplasia
corticosteroid
treatment
includ
assay
ml
serum
obtain
system
arteri
blood
sampl
taken
usual
medic
care
patient
icu
blood
sampl
obtain
patient
ard
patient
acp
within
first
h
follow
onset
lung
insult
sampl
store
serum
sampl
also
obtain
five
healthi
volunt
store
chang
distribut
cell
stiff
induc
leukocyt
popul
serum
incub
assess
take
systemat
measur
leukocyt
entri
time
et
microfluid
constrict
stiffen
effect
sera
patient
ard
first
test
primari
neutrophil
monocyt
cell
use
systemat
studi
sera
healthi
volunt
acp
ard
group
identifi
cytokin
potenti
involv
cell
stiffen
correl
mean
et
subject
three
group
cytokin
level
sera
recombin
cytokin
use
confirm
quantifi
stiffen
potenti
relev
cytokin
final
cytokineblock
antibodi
ab
ad
sera
analyz
respect
involv
cytokin
stiffen
effect
patient
sera
test
protect
effect
patholog
stiffen
effect
patient
sera
protocol
depict
figur
see
addit
file
cell
incub
sera
direct
microfluid
circuitri
vari
height
macroscop
reservoir
addit
file
figur
connect
microfluid
chip
posit
microscop
stage
addit
file
figur
et
microfluid
constrict
known
good
indic
cell
stiff
howev
devic
singl
constrict
found
poorli
adapt
cell
elev
stiff
mismatch
rectangular
crosssect
microfluid
channel
spheric
shape
cell
allow
flow
leakag
around
cell
addit
file
figur
induc
poor
et
reproduc
devic
use
studi
two
constrict
seri
similar
width
w
height
h
h
respect
addit
file
figur
e
cell
first
forc
constrict
occupi
entir
crosssect
channel
therefor
prevent
leak
corner
addit
file
figur
ii
cell
stiff
assess
examin
cell
passag
constrict
narrow
constrict
et
singl
cell
determin
examin
video
microscopi
sequenc
time
interv
lead
edg
cell
touch
entranc
constrict
trail
edg
cell
clear
entranc
constrict
addit
file
figur
iii
c
iv
microfluid
devic
fabric
use
standard
soft
lithographi
procedur
posit
mold
creat
resin
microchem
westborough
usa
silicon
wafer
siltronix
archamp
franc
replica
made
polydimethylsiloxan
elastom
dow
corn
auburn
mi
usa
seal
glass
cover
slide
via
plasma
activ
harrick
plasma
ithaca
ny
usa
channel
incub
pluron
f
solut
basf
florham
park
nj
usa
h
deter
cell
adhes
observ
made
use
invert
microscop
axio
observ
carl
zeiss
microscopi
oberkochen
germani
equip
phase
contrast
object
planneofluar
oil
carl
zeiss
microscopi
burl
camera
burl
primari
monocyt
neutrophil
isol
whole
blood
analyz
within
h
whole
blood
collect
heparin
vial
healthi
donor
provid
inform
consent
cell
stiff
measur
polymorphonuclear
cell
peripher
blood
mononuclear
cell
pbmc
separ
isol
whole
blood
gradient
densiti
centrifug
use
solut
sigmaaldrich
st
loui
mo
usa
monocyt
separ
pbmc
fraction
neg
select
use
pan
monocyt
isol
kit
human
miltenyi
biotec
bergisch
gladbach
germani
red
blood
cell
elimin
polymorphonuclear
fraction
via
hypoton
lysi
monocyt
cell
line
american
type
cultur
collect
manassa
va
usa
maintain
gibco
rpmi
medium
life
technolog
carlsbad
ca
usa
supplement
fetal
calf
serum
mm
lglutamin
incub
cell
patient
sera
perform
h
cytoskeleton
inhibit
perform
latrunculin
molecular
probe
eugen
usa
nocodazol
sigmaaldrich
minut
cytometr
analysi
use
ab
control
efficaci
lymphocyt
monocyt
neutrophil
purif
procedur
neutrophil
isol
whole
blood
neg
select
use
direct
human
neutrophil
isol
kit
stemcel
technolog
vancouv
bc
canada
monocyt
isol
pbmc
fraction
neg
select
use
pan
monocyt
isol
kit
human
miltenyi
biotec
lymphocyt
studi
use
pbmc
fraction
follow
adhes
functionblock
ab
human
adhes
molecul
use
antilselectin
chain
integrin
antiintegrin
chain
integrin
chain
integrin
chain
lymphocyt
functionassoci
antigen
integrin
biolegend
san
diego
ca
usa
discrimin
cell
cytometri
data
also
use
ab
biolegend
follow
ab
cytokin
use
abd
serotec
raleigh
nc
usa
janssen
biolog
bv
leiden
netherland
also
use
ab
control
experi
antimous
immunoglobulin
abd
serotec
mous
ebiosci
san
diego
ca
usa
human
polyclon
ab
lfb
biomedica
uli
franc
goat
abd
serotec
enzymelink
immunosorb
assay
elisa
kit
test
human
interferon
ifn
transform
growth
obtain
r
system
minneapoli
mn
usa
recombin
purchas
life
technolog
recombin
purchas
peprotech
rocki
hill
nj
usa
cytometr
measur
perform
bd
lsr
ii
flow
cytomet
bd
bioscienc
san
jose
ca
usa
label
perform
accord
manufactur
recommend
adhes
circul
leukocyt
model
endothelium
examin
vitro
use
laminar
flow
chamber
techniqu
human
umbil
vein
endotheli
cell
promocel
heidelberg
germani
cell
push
horizont
flow
sediment
graviti
vicin
endotheli
cell
monolay
cultur
confluenc
glass
substrat
coat
fibronectin
frequenc
cell
arrest
constant
hydrodynam
shear
stress
monitor
distribut
evalu
use
kolmogorovsmirnov
test
accord
variabl
distribut
differ
group
assess
use
oneway
analysi
varianc
post
hoc
tukey
test
student
test
mannwhitney
u
test
wilcoxon
test
fisher
exact
test
correl
et
cytokin
concentr
assess
use
spearman
test
p
valu
consid
signific
report
p
valu
twosid
mention
statist
analysi
conduct
use
ibm
spss
version
softwar
ibm
armonk
ny
usa
graph
creat
use
graphpad
prism
softwar
graphpad
softwar
la
jolla
ca
usa
twentytwo
patient
present
earli
ard
includ
thirteen
patient
classifi
tabl
typic
measur
microfluid
stiff
tester
present
fig
c
see
addit
file
addit
movi
file
show
detail
cell
incub
healthi
serum
fig
character
lognorm
distribut
wherea
ard
serum
incub
cell
fig
greatli
widen
distribut
two
popul
roughli
similar
size
one
popul
moder
stiffen
cell
et
one
order
magnitud
greater
healthi
cell
et
second
anoth
popul
highli
stiff
cell
et
two
order
magnitud
greater
healthi
cell
et
second
doubl
popul
distribut
gener
featur
ard
serum
incub
cell
primari
fresh
neutrophil
monocyt
line
cell
fig
sera
patient
ard
induc
rapid
intens
stiffen
show
stiffen
effect
sera
patient
ard
act
leukocyt
compar
sera
healthi
subject
sera
patient
acp
affect
stiffen
fig
wherea
sera
patient
mild
moder
sever
ard
increas
et
cell
henc
sera
patient
ard
induc
leukocyt
stiffen
wherea
cardiogen
edema
relev
paramet
process
find
support
hypothesi
leukocyt
stiffen
induc
serum
relat
sever
lung
injuri
due
ard
evalu
respect
role
ard
ss
compar
et
patient
present
ard
without
ss
patient
present
ard
ss
shown
fig
group
patient
present
ard
ss
higher
et
group
present
ard
without
ss
howev
group
patient
ard
without
ss
show
significantli
higher
et
healthi
subject
patient
acp
p
find
demonstr
specif
link
ard
leukocyt
stiffen
independ
presenc
ss
serum
level
cytokin
report
addit
file
tabl
found
posit
correl
et
cytokin
level
see
addit
file
figur
figur
show
recombin
maximum
concentr
found
patient
sera
induc
pronounc
stiffen
cell
wherea
signific
effect
furthermor
incub
cell
recombin
larg
excess
block
ab
affect
cell
stiff
compar
control
without
cytokin
ab
partial
revers
seruminduc
stiffen
antibodi
incub
cell
sera
patient
ard
block
ab
cytokin
fig
excess
block
ab
markedli
reduc
seruminduc
stiffen
wherea
block
ab
effect
result
prove
particip
significantli
leukocyt
stiffen
effect
induc
sera
patient
ard
nevertheless
cell
protect
three
block
ab
remain
significantli
stiffer
control
cell
suggest
factor
stiffen
process
induc
sera
synergist
effect
might
exist
mixtur
pgml
pgml
respect
induc
signific
synergist
effect
compar
isol
compon
figur
present
adhes
frequenc
cell
monolay
endotheli
cell
detect
chang
adhes
frequenc
acp
ard
without
ss
wherea
increas
frequenc
observ
ard
ss
adhes
measur
flow
suggest
increas
adhes
relat
ss
rather
ard
express
surfac
receptor
found
roughli
similar
group
healthi
donor
patient
ard
incub
h
h
lymphocyt
monocyt
h
h
neutrophil
fig
even
sera
patient
ss
induc
signific
upregul
surfac
receptor
concentr
serum
rpmi
medium
also
use
stiffen
experi
incub
cell
actin
polymer
inhibitor
latrunculin
found
inhibit
seruminduc
stiffen
great
extent
wherea
tubulin
polymer
inhibitor
nocodazol
neglig
impact
see
addit
file
figur
result
suggest
cell
stiffen
actindepend
present
studi
shown
serum
patient
ard
induc
rapid
intens
actindepend
stiffen
leukocyt
leukocyt
stiffen
associ
sever
ard
low
express
adhes
molecul
integrin
famili
suggest
leukocyt
stiffen
play
import
role
adhes
sequestr
lung
microvasculatur
earli
phase
ard
analysi
serum
composit
use
recombin
cytokin
show
cytokin
major
contributor
leukocyt
stiffen
sera
patient
ard
final
block
ab
found
protect
leukocyt
seruminduc
stiffen
variou
method
employ
evalu
leukocyt
deform
standard
tool
clinic
applic
microfiltr
experi
cell
transit
analysi
use
studi
sepsi
lung
injuri
transit
time
cell
suspens
micropor
filter
remain
qualit
distinguish
effect
adhes
stiff
possibl
assay
convers
singlecel
method
micropipett
aspir
cell
poker
atom
forc
microscopi
allow
precis
mechan
measur
throughput
low
medic
studi
strategi
use
microfluid
allow
one
design
higherthroughput
experi
adhes
stiff
mimic
target
physiolog
condit
geometri
approxim
pressur
pa
lung
microvasculatur
done
present
studi
fig
stiff
vs
lung
injuri
distribut
median
entri
time
et
measur
incub
cell
sera
healthi
donor
control
n
patient
acut
cardiogen
pulmonari
edema
acp
n
patient
mild
acut
respiratori
distress
syndrom
ard
n
among
septic
shock
ss
patient
moder
sever
ard
n
among
septic
shock
b
stiff
vs
ss
distribut
median
et
measur
incub
cell
sera
healthi
subject
n
patient
acp
n
patient
ard
without
septic
shock
n
patient
ard
septic
shock
n
number
test
cell
per
patient
box
plot
repres
median
black
bar
insid
box
interquartil
rang
box
minimum
maximum
valu
whisker
p
p
p
mannwhitney
u
test
chose
studi
stiffen
leukocyt
use
cell
mainli
cell
line
freshli
isol
primari
neutrophil
allow
establish
stabl
reproduc
analysi
protocol
relev
use
monocyt
cell
line
analyz
ard
mechan
arguabl
howev
research
studi
report
evid
neutrophilindepend
mechan
ard
support
nonneglig
role
type
leukocyt
suggest
monocyt
inde
contribut
substanti
neutrophil
recruit
lung
pulmonari
inflamm
injuri
mous
model
addit
cell
line
model
support
strong
similar
cell
monocyt
regard
migrat
stimul
nformylmethionylleucylphenylalanin
phospholipas
activ
adhes
increas
mechan
strength
adhes
endotheli
cell
induc
monocyt
colonystimul
factor
stimul
coronaviru
respons
ardslik
syndrom
bind
chemotact
factor
cell
neutrophil
final
show
stiffen
effect
sera
patient
ard
ubiquit
cell
monocyt
neutrophil
abnorm
leukocyt
stiff
report
previou
studi
ss
ard
data
provid
first
evid
best
knowledg
leukocyt
stiffen
intrins
characterist
ard
independ
presenc
ss
cardiogen
pulmonari
edema
best
knowledg
investig
studi
leukocyt
stiff
ard
measur
report
leukocyt
popul
moder
stiffen
cell
extrem
high
stiff
also
found
bimod
distribut
interestingli
popul
highli
stiff
cell
repres
data
approxim
cell
find
suggest
earlier
studi
patient
cell
could
bias
trap
stiffest
cell
patient
microvasculatur
wherea
serumbas
find
larg
proport
stiffen
cell
would
repres
patient
whole
leukocyt
popul
studi
also
first
demonstr
leukocyt
stiffen
induc
incub
sera
patient
ard
serum
stiffen
effect
rather
rapid
h
compat
role
earli
trigger
leukocyt
sequestr
microvasculatur
end
associ
sever
ard
leukocyt
stiffen
presenc
leukocyt
stiffen
independ
ss
support
intrins
role
leukocyt
stiff
pathogenesi
lung
injuri
regard
leukocyt
adhes
evalu
express
integrin
receptor
literatur
show
limit
rather
slow
upregul
adhes
molecul
plasma
patient
sepsi
eg
neutrophil
sampl
similar
incub
condit
faint
effect
adhes
molecul
upregul
detect
wherea
cell
stiffen
found
fast
strong
find
suggest
circul
factor
might
favor
leukocyt
adhes
delay
sever
hour
interestingli
adhes
shown
laminar
flow
experi
exposur
ard
sera
significantli
increas
demonstr
adhes
might
play
major
role
earli
ard
end
one
could
conclud
leukocyt
arrest
microvasculatur
ard
might
trigger
rapid
leukocyt
stiffen
earli
time
point
within
h
wherea
adhes
may
develop
later
stage
interestingli
similar
scenario
previous
propos
patholog
increas
report
patient
sepsi
leukocyt
sequestr
data
howev
found
correl
leukocyt
stiffen
suggest
role
domin
inde
leukocyt
stiffen
appear
vitro
concentr
pgml
much
higher
content
sera
patient
ard
found
induc
leukocyt
stiffen
similar
effect
report
concentr
threshold
pgml
show
signific
stiffen
effect
pgml
pgml
previou
research
report
effect
pgml
transient
h
effect
pgml
found
strong
stiffen
within
h
pgml
experi
ab
confirm
direct
particip
three
cytokin
stiffen
effect
serum
monoblockad
significantli
reduc
effect
howev
result
pure
recombin
sera
mix
ab
cytokin
suggest
substanc
remain
identifi
play
addit
andor
synergist
role
yet
therapeut
treatment
revers
abnorm
leukocyt
stiffen
cytochalasin
effici
system
toxic
pentoxifyllin
phosphodiesteras
inhibitor
reduc
neutrophil
stiffen
efficaci
treat
hemorrhag
shock
found
limit
block
ab
provid
weak
prophylact
poor
therapeut
effect
larg
cohort
patient
sepsi
nevertheless
patient
sepsi
lung
injuri
might
benefit
blockad
multipl
cytokin
pathway
research
recent
studi
mice
human
report
benefici
respons
case
acut
lung
injuri
sepsi
result
regard
protect
stiffen
block
ab
support
explor
cytokin
regul
therapeut
purpos
previou
unsuccess
clinic
assay
base
longterm
treatment
futur
assay
could
benefit
regular
monitor
leukocyt
stiff
treatment
microfluid
tool
adjust
treatment
dose
time
rational
would
also
help
therapeut
approach
treatment
sivelestat
neutrophil
elastas
inhibitor
limit
leukocyt
stiffen
vitro
benefit
pulmonari
function
improv
surviv
patient
ard
sepsi
shown
serum
patient
ard
induc
rapid
intens
actindepend
stiffen
leukocyt
leukocyt
stiffen
associ
sever
ard
low
induct
patient
sera
adhes
endotheli
cell
upregul
adhes
molecul
suggest
leukocyt
stiffen
play
import
role
sequestr
lung
microvasculatur
earli
phase
ard
stiffen
larg
part
induc
increas
level
sera
patient
ard
ab
three
cytokin
protect
leukocyt
seruminduc
stiffen
